Triclosan
DERMATOLOGICALS
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Triclosan is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1997. DrugCentral lists 13 molecular targets, including fabI, ENR and fabI.
- Approval status: ofm (first approved 1997 by the FDA).
- Molecular targets: fabI, ENR, fabI and CBR1 (13 listed in DrugCentral).
- ATC code: D08AE04 (Phenol and derivatives).
- Molecular formula: C12H7Cl3O2; molecular weight 289.54 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Contraindications (5)
- Conduction disorder of the heart
- Decreased respiratory function
- Denuded skin
- Open wound
- Seizure disorder
Mechanism & targets
Molecular targets (13)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Enoyl-acyl-carrier protein reductase | fabI | unknown | Ki 10.28 |
| Enoyl-acyl carrier reductase; Enoyl-acyl carrier reductase ENR | ENR | unknown | IC50 7.82 |
| Enoyl-[acyl-carrier-protein] reductase [NADPH] | fabI | unknown | IC50 7.23 |
| Carbonyl reductase [NADPH] 1 | CBR1 | unknown | Ki 7.22 |
| Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI | fabI | unknown | IC50 7.15 |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | inhA | unknown | Ki 6.70 |
| Enoyl-ACP reductase | FabI | unknown | IC50 6.70 |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | inhA | unknown | Ki 6.70 |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | fabI | inhibitor | IC50 6.37 |
| Transthyretin | TTR | unknown | Kd 6.32 |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | fabI | unknown | IC50 6.30 |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | fabI | unknown | IC50 5.89 |
| 78 kDa glucose-regulated protein | HSPA5 | unknown | IC50 4.00 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1997-07-11 | FDA | — | COLGATE PALMOLIVE |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
D08AE04 | DERMATOLOGICALS › ANTISEPTICS AND DISINFECTANTS › ANTISEPTICS AND DISINFECTANTS › Phenol and derivatives |
D09AA06 | DERMATOLOGICALS › MEDICATED DRESSINGS › MEDICATED DRESSINGS › Medicated dressings with antiinfectives |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Joint dislocation | 368.5 |
| Seronegative arthritis | 304.8 |
| Joint stiffness | 280.5 |
| Prescribed underdose | 274.6 |
| Wound infection | 242.3 |
| Walking aid user | 233.1 |
| Retinitis | 223.2 |
| Lupus vulgaris | 221.9 |
| Joint range of motion decreased | 209.3 |
| Laryngitis | 205.0 |
| Lupus-like syndrome | 204.5 |
| Hypercholesterolaemia | 196.5 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Triclosan is on its molecule page.
| Molecular formula | C12H7Cl3O2 |
|---|---|
| Molecular weight | 289.54 g/mol |
| CAS number | 3380-34-5 |
| InChIKey | XEFQLINVKFYRCS-UHFFFAOYSA-N |
| PubChem CID | 5564 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
How does Triclosan work?
Its molecular targets in DrugCentral include fabI, ENR, fabI and CBR1.
When was Triclosan first approved?
Triclosan was first approved by the FDA in 1997.
What is the chemical formula of Triclosan?
Triclosan has the molecular formula C12H7Cl3O2 and a molecular weight of 289.54 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 3631 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL849 — compound record and bioactivity
- PubChem CID 5564 — chemical identifiers
- DrugBank DB08604 — drug record
- FDA UNII 4NM5039Y5X — substance identity
- DailyMed: FDA labels for Triclosan — current prescribing information (label search)
- UniProt P16152 (CBR1) — target protein
- UniProt P02766 (TTR) — target protein
- UniProt P11021 (HSPA5) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.